These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 4736242)

  • 1. Synthese of flufenamie acid metabolites I and II and other N-arylanthranilie acids.
    Bowman RE; Brunt KO; Godfrey KE; Kruszynska L; Reynolds AA; Thrift RI; Waite D; Williamson WR
    J Chem Soc Perkin 1; 1973; 1():1-4. PubMed ID: 4736242
    [No Abstract]   [Full Text] [Related]  

  • 2. [The preparation of N-arylated 5-methoxyanthranilic acids].
    Hannig E; Becke E
    Pharmazie; 1975 May; 30(5):289-90. PubMed ID: 1178737
    [No Abstract]   [Full Text] [Related]  

  • 3. Tolfenamic acid. Detection and structure of urinary metabolites.
    Pedersen SB; Alhede B; Buchardt O; Møller J; Bock K
    Arzneimittelforschung; 1981; 31(11):1944-8. PubMed ID: 7198475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Reactions with anthranilamides. V. Synthesis of 1,2,3,4-tetrahydro-2-spiro-(2'-tetrahydrofurano) quinazoline-3-substituted and of 2-(N-pyrrolidin-2-on) aminobenzamides].
    Landi Vittory R; Gatta F
    Farmaco Sci; 1972 Mar; 27(3):208-16. PubMed ID: 5022160
    [No Abstract]   [Full Text] [Related]  

  • 5. Purification and 1H NMR spectroscopic characterization of phase II metabolites of tolfenamic acid.
    Sidelmann UG; Christiansen E; Krogh L; Cornett C; Tjørnelund J; Hansen SH
    Drug Metab Dispos; 1997 Jun; 25(6):725-31. PubMed ID: 9193874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [On various derivatives of mefenamic and flufenamic acids].
    Spanò R; Marri R
    Boll Chim Farm; 1968 Aug; 107(8):512-5. PubMed ID: 5721222
    [No Abstract]   [Full Text] [Related]  

  • 7. Structure-activity relationships in a series of anti-inflammatory N-arylanthranilic acids.
    Kaltenbronn JS; Scherrer RA; Short FW; Jones EM; Beatty HR; Saka MM; Winder CV; Wax J; Williamson WR
    Arzneimittelforschung; 1983; 33(4A):621-7. PubMed ID: 6683967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical study of a new anthranilic acid derivative: flufenamic acid].
    Colombo B; Chériè Lignière G; Mantellini P
    Reumatismo; 1969; 21(3):114-21. PubMed ID: 4929605
    [No Abstract]   [Full Text] [Related]  

  • 9. [Flufenamic acid].
    Südhof H
    Dtsch Med Wochenschr; 1968 Dec; 93(50):2455. PubMed ID: 5698984
    [No Abstract]   [Full Text] [Related]  

  • 10. [Analytical reactions of mefenamic and flufenamic acids].
    Devaux G; Mesnard P; Brisson AM
    Ann Pharm Fr; 1969 Mar; 27(3):239-48. PubMed ID: 5400246
    [No Abstract]   [Full Text] [Related]  

  • 11. [Experiments in the synthesis of anthranilic acid amides].
    Wagner G; Rothe L
    Pharmazie; 1971 May; 26(5):271-7. PubMed ID: 5563056
    [No Abstract]   [Full Text] [Related]  

  • 12. On the effect on human thrombocytes of synthetic organic fibrinolytic compounds.
    Molinas F; von Kaulla KN
    Thromb Diath Haemorrh; 1969 Feb; 21(1):46-64. PubMed ID: 5773729
    [No Abstract]   [Full Text] [Related]  

  • 13. Optical studies of drug-protein complexes. 3. Interaction of flufenamic acid and other N-arylanthranilates with serum albumin.
    Chignell CF
    Mol Pharmacol; 1969 Sep; 5(5):455-62. PubMed ID: 5823761
    [No Abstract]   [Full Text] [Related]  

  • 14. [Pharmacological properties of a series of derivatives of mefenamic and flufenamic acids].
    Linari G; Spanò R
    Farmaco Sci; 1971 Apr; 26(4):303-11. PubMed ID: 5559990
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical results in the treatment of rheumatic diseases using flufenamic acid].
    Peña González A
    Rev Esp Reum Enferm Osteoartic; 1968 Oct; 12(8):217-8. PubMed ID: 5307372
    [No Abstract]   [Full Text] [Related]  

  • 16. Flufenamic acid in rheumatoid arthritis.
    Drug Ther Bull; 1967 Dec; 5(26):103-4. PubMed ID: 6078914
    [No Abstract]   [Full Text] [Related]  

  • 17. [Synthesis and pharmacologic property of anthranilic acid-N-(aryl-substitutes)].
    Picciola G; Gaggi R; Caliari W
    Farmaco Sci; 1968 May; 23(5):502-11. PubMed ID: 5680389
    [No Abstract]   [Full Text] [Related]  

  • 18. [Relationship between the structure of N-phenylanthranilic acid derivatives and their antiphlogistic action. II].
    Grasser K; Petöcz L; Görög P
    Acta Pharm Hung; 1973 Jul; 43(3):158-61. PubMed ID: 4747713
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical experience with the flufenamic acid--thyocolchicoside combination].
    López Prats JL
    Rev Esp Reum Enferm Osteoartic; 1970 Jul; 13(7):405-12. PubMed ID: 5501543
    [No Abstract]   [Full Text] [Related]  

  • 20. Experimental observations on flufenamic, mefanamic and meclofenamic acids. II. Toxicology in animals.
    Kaump DH
    Ann Phys Med; 1966; Suppl():16-23. PubMed ID: 4979051
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.